
Am J Psychiatry 160:1413-1420, August 2003
© 2003 American Psychiatric Association
Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Rodrigo A. Bressan, M.D., Ph.D.,
Kjell Erlandsson, Ph.D.,
Hugh M. Jones, M.R.C.Psych.,
Rachel Mulligan, B.Sc., M.Sc., Ph.D.,
Robert J. Flanagan, B.Sc., Ph.D., F.R.S.C., F.R.C.Path.,
Peter J. Ell, M.D., Ph.D., F.R.C.P., M.R.C.R., F.Med.Sci., and
Lyn S. Pilowsky, M.R.C.Psych., Ph.D.
OBJECTIVE: Atypical antipsychotic drug treatment is clinically effective with a low risk of extrapyramidal symptoms. Explanations for the mechanism underlying this beneficial therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous antagonism of dopamine D2 and serotonin 5-HT2A receptors or 2) selective action at limbic cortical dopamine D2-like receptors with modest striatal D2 receptor occupancy. Amisulpride is an atypical antipsychotic drug with selective affinity for D2/D3 dopamine receptors and provides a useful pharmacological model for examining these hypotheses. The authors goal was to evaluate whether treatment with amisulpride results in "limbic selective" D2/D3 receptor blockade in vivo. METHOD: Five hours of dynamic single photon emission tomography data were acquired after injection of [123I]epidepride (approximately 150 MBq). Kinetic modeling was performed by using the simplified reference region model to obtain binding potential values. Estimates of receptor occupancy were made relative to a healthy volunteer comparison group (N=6). RESULTS: Eight amisulpride-treated patients (mean dose=406 mg/day) showed moderate levels of D2/D3 receptor occupancy in the striatum (56%), and significantly higher levels were seen in the thalamus (78%) and temporal cortex (82%). CONCLUSIONS: Treatment with amisulpride results in a similar pattern of limbic cortical over striatal D2/D3 receptor blockade to that of other atypical antipsychotic drugs. This finding suggests that modest striatal D2 receptor occupancy and preferential occupancy of limbic cortical dopamine D2/D3 receptors may be sufficient to explain the therapeutic efficacy and low extrapyramidal symptom profile of atypical antipsychotic drugs, without the need for 5-HT2A receptor antagonism.
This article has been cited by other articles:

|
 |

|
 |
 
J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky
Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
Schizophr Bull,
July 1, 2009;
35(4):
789 - 797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Gibbs, K. H. Naudts, E. P. Spencer, and A. S. David
The Role of Dopamine in Attentional and Memory Biases for Emotional Information
Am J Psychiatry,
October 1, 2007;
164(10):
1603 - 1609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol,
June 1, 2007;
21(4):
440 - 452.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Am J Psychiatry,
March 1, 2006;
163(3):
396 - 401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Tremblay, C. A. Naranjo, S. J. Graham, N. Herrmann, H. S. Mayberg, S. Hevenor, and U. E. Busto
Functional Neuroanatomical Substrates of Altered Reward Processing in Major Depressive Disorder Revealed by a Dopaminergic Probe
Arch Gen Psychiatry,
November 1, 2005;
62(11):
1228 - 1236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. la Fougere, E. Meisenzahl, G. Schmitt, J. Stauss, T. Frodl, K. Tatsch, K. Hahn, H.-J. Moller, and S. Dresel
D2 Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A 123I-Iodobenzamide SPECT Study
J. Nucl. Med.,
June 1, 2005;
46(6):
1028 - 1033.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|